XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 28, 2025
Jun. 28, 2024
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-41245    
Entity Registrant Name CONDUIT PHARMACEUTICALS INC.    
Entity Central Index Key 0001896212    
Entity Tax Identification Number 87-3272543    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 4581 Tamiami Trail North    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town Naples    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 34103    
City Area Code (646)    
Local Phone Number 491-9132    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 41,401,162
Entity Common Stock, Shares Outstanding   6,662,755  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.0001    
Auditor Firm ID 688    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Conduit Pharmaceuticals Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders’ deficit and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Marcum LLP    
Auditor Location Morristown, NJ    
Common Stock, par value $0.0001 per share      
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol CDT    
Security Exchange Name NASDAQ    
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50      
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $1,150    
Trading Symbol CDTTW    
Security Exchange Name NASDAQ